NASDAQ · SOPH
SOPHiA GENETICS S.A.
$7.97+$0.10 (+1.27%)
SOPHiA GENETICS S.A.’s quoted price sits in the upper half of its reported 52-week range, 11.25% below the high.
Loading market information…
NASDAQ · OPRX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
OptimizeRx Corp.’s quoted price sits in the lower half of its reported 52-week range, 55.57% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
OptimizeRx Corp.’s next earnings report is currently expected on Nov 10, 2026, with estimated earnings per share of $0.18. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow OptimizeRx Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:24 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 12, 2025 | $0.08+172.73% vs estimate | $21.93M+17.35% vs estimate |
|---|
| Q4 2024 | Mar 12, 2025 | $0.30+20.0% vs estimate | $32.32M+72.09% vs estimate |
|---|
| Q3 2024 | Nov 13, 2024 | $0.12+100.0% vs estimate | $21.31M-29.37% vs estimate |
|---|
THE ANALYST VIEW
15 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 4 contributors · Median target $11.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.97+$0.10 (+1.27%)
SOPHiA GENETICS S.A.’s quoted price sits in the upper half of its reported 52-week range, 11.25% below the high.
$56.69+$1.37 (+2.48%)
Bright Minds Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.19% below the high.
$23.49+$0.02 (+0.09%)
NRC Health’s quoted price sits in the upper half of its reported 52-week range, 3.73% below the high.
$26.24$0.00 (0.0%)
TruBridge, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.02% below the high.
$18.50$0.00 (0.0%)
Simulations Plus, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.95% below the high.
$20.33-$1.04 (-4.87%)
Semler Scientific, Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.19% below the high.
$11.78+$1.60 (+15.72%)
Spok Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 19.2% below the high.
$5.05+$0.15 (+3.06%)
RxSight, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.8% below the high.
